5/17/2018 | CV | New Issue: Biodelivery Sciences places $50 million convertible preferred stock
|
2/23/2017 | HYIG | Market Commentary: First Industrial Realty Trust, NexBank, BioDelivery Sciences arrange private placements
|
2/23/2017 | PV | BioDelivery enters into up to $75 million credit facility with CRG
|
2/10/2014 | PP | BioDelivery arranges $60 million registered direct offering of stock
|
7/8/2013 | PP | BioDelivery secures $20 million through three-year senior secured loan
|
7/8/2013 | PV | BioDelivery secures $20 million through three-year senior secured loan
|
11/28/2012 | PP | BioDelivery plans $40 million direct sale of common stock, preferreds
|
1/31/2012 | CVPF | BioDelivery files $40 million shelf covering debt, stock, preferreds
|
3/11/2011 | PP | BioDelivery Sciences negotiates $15 million private placement of stock
|
4/20/2010 | PP | New Issue: BioDelivery Sciences arranges $10 million registered offering of stock
|
4/20/2010 | PP | Market Commentary: Monmouth Real Estate to sell stock; Coalspur Mines seeks A$30 million; La Cortez wraps tranche
|
8/4/2009 | SS | BioDelivery Sciences shareholder Elliott reduces ownership to 9%
|
7/23/2009 | SS | BioDelivery Sciences shareholder Elliott reduces stake to 9.5%
|
7/20/2009 | SS | BioDelivery Sciences investor CDC IV sells shares, keeps 11.5% stake
|
7/17/2009 | SS | BioDelivery Sciences investor Elliott Associates trims stake to 12.3%
|
7/9/2009 | SS | BioDelivery Sciences shareholder CDC IV reduces stake to 12.31%
|
7/7/2009 | SS | BioDelivery Sciences investor CDC IV cuts ownership interest to 13.1%
|
7/2/2009 | SS | BioDelivery Sciences investor CDC IV sells shares, keeps 12.7% stake
|
6/26/2009 | SS | BioDelivery Sciences investor CDC IV sells shares, keeps 16.2% stake
|
6/22/2009 | SS | BioDelivery Sciences shareholder Elliott reduces stake to 17.5%
|
6/17/2009 | SS | BioDelivery Sciences shareholder Elliott Associates has 18.8% stake
|
1/21/2009 | CV | BioDelivery Sciences files $50 million shelf
|
9/13/2007 | SS | Hopkins Capital acquires warrants for shares of BioDelivery Sciences
|
1/4/2007 | PP | BioDelivery Sciences issues additional warrants to Laurus to defer payments
|
10/19/2006 | BT | Market Commentary: Asthmatx on deck; Ariad slides after-hours; Siga slips on PIPE; Accentia rises 42% on trial data
|
9/26/2006 | BT | BioDelivery to restart BEMA Fentanyl trials in California
|
9/20/2006 | BT | BioDelivery Sciences to file NDA for BEMA Fentanyl next year
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/31/2006 | BT | BioDelivery, Clinical Development dispute alleged breach
|
8/24/2006 | BT | BioDelivery rejects Clinical Development Capital's Fentanyl plans
|
8/16/2006 | BT | BioDelivery reports positive results from proof-of-concept study of BEMA LA for pain
|
8/4/2006 | BTPP | BioDelivery Sciences issues warrants to Laurus to defer payments
|
8/3/2006 | BT | BioDelivery, Meda announce European licensing agreement on BEMA Fentanyl
|
7/17/2006 | BT | BioDelivery Sciences submits Emezine pharmacokinetic study designs to the FDA
|
6/9/2006 | BT | BioDelivery Sciences to conduct additional Emezine studies
|
5/17/2006 | BT | BioDelivery Sciences converts funding to stock, raises $4.2 million cash in $7 million transaction
|
4/24/2006 | BT | BioDelivery Sciences confirms dose proportionality with BEMA Fentanyl
|
4/3/2006 | BTPP | BioDelivery Sciences extends $4 million equity line
|
3/2/2006 | BT | Accentia partner BioDelivery gets FDA non-approvable letter for Emezine
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
2/16/2006 | BT | BioDelivery Sciences gets $2 million milestone payment for pain medication development
|
1/6/2006 | BT | BioDelivery Sciences files FDA application for quick-dissolving pain drug formulation
|
1/3/2006 | BTPP | BioDelivery Sciences get payment deferral on $5 million convertibles
|
12/7/2005 | BT | BioDelivery: Study of Emezine buccal tablets promising, may offer option for nausea patients
|
11/28/2005 | BT | BioDelivery Sciences to start clinical work on BEMA LA, plans phase 3 trial in second half of 2006
|
11/1/2005 | BT | BioDelivery Sciences prepares phase III trial for BEMA fentanyl after positive study results
|
10/28/2005 | BT | BioDelivery Sciences greenshoe partially exercised, raising $107,900
|
9/30/2005 | BT | New Issue: BioDelivery raises $8.8 million in downsized follow-on of 4.4 million shares at $2
|
9/30/2005 | BT | Market Commentary: Predix IPO price range emerges; Genomic, Avalon, Sunesis a mix; Progenics up; BioDelivery slides
|
8/8/2005 | BT | Market Commentary: Isis declines on earnings, Lilly note conversion but 5.5% convert finds bids; Quest, LabOne higher
|
8/3/2005 | BT | BioDelivery Sciences files for 7.02 million share follow-on stock offering
|
7/21/2005 | BT | BioDelivery Sciences obtains $7 million financing from Clinical Development Capital
|
6/30/2005 | BTPP | BioDelivery gets payment deferral on $5 million convertibles
|
6/3/2005 | PP | New Issue: BioDelivery places additional $2.5 million of convertibles
|
6/3/2005 | PP | Market Commentary: PIPE volume weakens at week's end due to lower stocks; PPOL wraps $10.2 million offering
|
2/23/2005 | PP | New Issue: BioDelivery Sciences wraps $2.5 million private placement of note
|
2/23/2005 | PP | Market Commentary: Canadians lead private placement volume; Bankers Petroleum plans C$35.65 million deal
|